1
|
Reiss AB, Saeedullah U, Grossfeld DJ, Glass AD, Pinkhasov A, Katz AE. Prostate cancer treatment and the relationship of androgen deprivation therapy to cognitive function. Clin Transl Oncol 2021; 24:733-741. [PMID: 34743290 DOI: 10.1007/s12094-021-02727-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Accepted: 10/23/2021] [Indexed: 02/01/2023]
Abstract
Prostate cancer is the second most common form of cancer in men. For advanced, high risk prostate cancer, androgen deprivation therapy (ADT) is the preferred treatment and can induce remission, but resistance to ADT brings biochemical recurrence and progression of cancer. ADT brings adverse effects such as erectile dysfunction, decreased libido, and diminished physical strength. It is estimated that between 25 and 50% of men on ADT manifest some form of cognitive dysfunction that may be self-reported or reported by a family member. There is concern that impaired cognitive function with ADT is due to loss of testosterone support. Testosterone and its metabolites are known to possess neuroprotective properties. While a direct causal relationship between ADT and cognitive decline in prostate cancer patients has not been established, this review describes the controversy surrounding the possible connection between ADT and neurocognitive deterioration. The cellular and molecular mechanisms believed to underlie the protection of neuronal integrity by androgens are discussed. Results from animal models and human clinical studies are presented. Finally, we call attention to lifestyle modifications that may minimize cognitive issues in prostate cancer patients.
Collapse
Affiliation(s)
- A B Reiss
- Biomedical Research Institute, NYU Long Island School of Medicine, 101 Mineola Boulevard, Suite 4-004, Mineola, NY, 11501, USA.
| | - U Saeedullah
- Biomedical Research Institute, NYU Long Island School of Medicine, 101 Mineola Boulevard, Suite 4-004, Mineola, NY, 11501, USA
| | - D J Grossfeld
- Biomedical Research Institute, NYU Long Island School of Medicine, 101 Mineola Boulevard, Suite 4-004, Mineola, NY, 11501, USA
| | - A D Glass
- Biomedical Research Institute, NYU Long Island School of Medicine, 101 Mineola Boulevard, Suite 4-004, Mineola, NY, 11501, USA
| | - A Pinkhasov
- Biomedical Research Institute, NYU Long Island School of Medicine, 101 Mineola Boulevard, Suite 4-004, Mineola, NY, 11501, USA
| | - A E Katz
- Biomedical Research Institute, NYU Long Island School of Medicine, 101 Mineola Boulevard, Suite 4-004, Mineola, NY, 11501, USA
| |
Collapse
|
2
|
Ashley MJ. Testosterone, sex steroids, and aging in neurodegenerative disease after acquired brain injury: a commentary. Brain Inj 2020; 34:983-987. [PMID: 32497444 DOI: 10.1080/02699052.2020.1763461] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
PRIMARY OBJECTIVE Traumatic brain injury (TBI) is associated with higher incidence of neurodegenerative disease and the effects of aging appear more pronounced after TBI. This paper examines the potential interaction of aging, TBI, and change in male testosterone production. METHODS AND PROCEDURES An abbreviated review of literature documenting hypogonadism after TBI is provided. Potential mechanisms of endocrine dysgrasia associated with aging are reviewed as they relate and interact with endocrine change after TBI in males. These factors align to suggest the need for development of surveillance guidelines for male individuals living with TBI. OUTCOMES AND RESULTS The neuroprotectant, neuroactivation, growth, and cell therapy characteristics of testosterone in the central nervous system are considerable. Age-related decrements in testosterone production may be accelerated after TBI. CONCLUSIONS Testosterone deficiency in male individuals after TBI can be present after TBI or can develop during aging. Age-related decreases in testosterone production after TBI may act to amplify endocrine dysfunction after TBI. Ongoing clinical surveillance for testosterone deficiency associated with both TBI and aging may be reasonable.
Collapse
Affiliation(s)
- Mark J Ashley
- Centre for Neuro Skills , Bakersfield, CA, USA.,School of Health Sciences, Southern Illinois University , Carbondale, IL, USA.,Department of Physical Therapy, Virginia Commonwealth University , Richmond, USA
| |
Collapse
|
3
|
Lašaitė L, Čeponis J, Preikša RT, Žilaitienė B. Effects of two-year testosterone replacement therapy on cognition, emotions and quality of life in young and middle-aged hypogonadal men. Andrologia 2016; 49. [PMID: 27545990 DOI: 10.1111/and.12633] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/11/2016] [Indexed: 12/18/2022] Open
Abstract
The aim of the study was to examine the effects of two-year testosterone replacement therapy on cognitive functioning, emotional state and quality of life in young and middle-aged men with hypogonadotropic hypogonadism. Nineteen males diagnosed with hypogonadotropic hypogonadism participated in the study. Cognitive functions were assessed by Trail Making Test and Digit Span Test of Wechsler Adult Intelligence Scale. Emotional state was evaluated by Profile of Mood States. Quality of life was evaluated by WHO Brief Quality of Life Questionnaire. Changes after two-year testosterone replacement therapy were detected in Trail Making A (42.9 ± 22.3 vs. 36.2 ± 22.5, p = .050) and B (90.6 ± 55.3 vs. 65.6 ± 21.4, p = .025) tests, showing improvement in attention and visual scanning abilities, executive function and psychomotor speed, as well as in Digit Span Test forward score (5.4 ± 2.0 vs. 6.1 ± 2.6, p = .046), showing improvement in attention capacity and psychomotor speed. No significant differences were observed in emotional state and quality of life. In conclusion, beneficial effect in cognitive functioning (improved attention and visual scanning ability, executive function and psychomotor speed), but not in emotional state and quality of life, was observed in young and middle-aged hypogonadal men after two-year testosterone replacement therapy.
Collapse
Affiliation(s)
- L Lašaitė
- Institute of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania
| | - J Čeponis
- Institute of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania
| | - R T Preikša
- Institute of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania
| | - B Žilaitienė
- Institute of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania
| |
Collapse
|
4
|
Lašaitė L, Ceponis J, Preikša RT, Zilaitienė B. Impaired emotional state, quality of life and cognitive functions in young hypogonadal men. Andrologia 2013; 46:1107-12. [PMID: 24313565 DOI: 10.1111/and.12199] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/07/2013] [Indexed: 11/30/2022] Open
Abstract
The study aimed to analyse emotional state, quality of life and cognitive functions in young hypogonadal men. Thirty-four males with hypogonadism (age 29.1 ± 10.5 years) and 34 age-matched healthy males (age 30.5 ± 11.0 years) were recruited. Their emotional state was evaluated by Profile of Mood States, quality of life - by WHO Brief Quality of Life Questionnaire - and cognitive functioning - by Trail Making Test and Digit Span Test of Wechsler Adult Intelligence Scale. It was found that young men with hypogonadism had higher depression-dejection (13.1 ± 8.8 versus 7.4 ± 5.9, P = 0.003), fatigue-inertia (10.0 ± 5.8 versus 7.0 ± 4.9, P = 0.030), confusion-bewilderment (5.1 ± 4.6 versus 2.3 ± 3.1, P = 0.004) and lower vigour-activity (14.3 ± 5.1 versus 17.7 ± 4.3, P = 0.008) levels than age- and sex-matched controls. Quality of life psychological (13.1 ± 2.8 versus 15.1 ± 1.9, P = 0.005) and social (13.6 ± 2.4 versus 15.7 ± 2.0, P < 0.001) domains were significantly worse in men with hypogonadism than in controls. Cognitive functions were significantly worse (P < 0.001) in men with hypogonadism than in controls, showing worse executive function, attention, visual scanning abilities and psychomotor speed. A significant correlation was found between testosterone concentration and quality of life psychological domain. Cognitive functioning scores were significantly related with FT4 concentration. It is concluded that young hypogonadal patients have impaired emotional state and quality of life, but the most severe impairment was found in cognitive functioning.
Collapse
Affiliation(s)
- L Lašaitė
- Institute of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania
| | | | | | | |
Collapse
|
5
|
5Alpha-dihydrotestosterone up-regulates transthyretin levels in mice and rat choroid plexus via an androgen receptor independent pathway. Brain Res 2008; 1229:18-26. [PMID: 18634756 DOI: 10.1016/j.brainres.2008.06.095] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2008] [Revised: 06/16/2008] [Accepted: 06/20/2008] [Indexed: 11/23/2022]
Abstract
Transthyretin (TTR) is a 55 kDa plasma homotetrameric protein mainly synthesized in the liver and choroid plexuses (CPs) of the brain that, functions as a carrier for thyroxin and retinol binding protein. It sequesters amyloid beta (Abeta) peptide, and TTR levels in the cerebrospinal fluid (CSF) appear to be inversely correlated with Alzheimer's disease (AD) onset and progression. Androgen deprivation increases plasma Abeta levels, which indicate that androgens may reduce the levels of soluble Abeta, the peptide widely implicated in the initiation of AD pathogenesis; however, the underlying mechanisms are still poorly understood. In this study we examined the effects of 5alpha-dihydrotestosterone (DHT) on TTR protein and mRNA levels, in primary cultures of rat CPs epithelial cells (CPEC) by Western blot, and real time PCR, respectively. Moreover, TTR concentrations were measured in the CSF of castrated wild-type, and transgenic mice expressing human TTR subjected to DHT treatment, by radioimmunoassay and ELISA, respectively. TTR mRNA expression was also compared in the CPs, of the animals from each experimental group by real time PCR. DHT treatment increased TTR protein levels in CPEC, and induced TTR transcription in these cells. The combination of flutamide with DHT in the treatment of CPEC did not abrogate DHT-induced TTR levels, suggesting that TTR is up-regulated via an androgen receptor independent pathway. In the CPs of both mice strains, DHT also increased TTR mRNA levels, but no significant differences in TTR protein levels were detected in the CSF of these animals. These findings open a wide range of possibilities for future studies on Abeta deposition and cognitive function, in response to androgen induction of TTR in animal models of AD.
Collapse
|
6
|
Braverman ER, Chen TJH, Prihoda TJ, Sonntag W, Meshkin B, Downs BW, Mengucci JF, Blum SH, Notaro A, Arcuri V, Varshavskiy M, Blum K. Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: evidence supported by structural equation modeling (SEM) parameter estimates. AGE (DORDRECHT, NETHERLANDS) 2007; 29:55-67. [PMID: 19424831 PMCID: PMC2267660 DOI: 10.1007/s11357-007-9030-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/09/2006] [Revised: 02/13/2007] [Accepted: 02/26/2007] [Indexed: 05/27/2023]
Abstract
A review of the literature in both animals and humans reveals that changes in sex hormone have often been associated with changes in behavioral and mental abilities. Previously published research from our laboratory, and others, provides strong evidence that P300 (latency) event-related potential (ERP), a marker of neuronal processing speed, is an accurate predictor of early memory impairment in both males and females across a wide age range. It is our hypothesis, given the vast literature on the subject, that coupling growth hormones (insulin-like growth factor-I, (IGF-I) and insulin-like growth factor binding protein 3 (IGF-BP3)), P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting. To support this hypothesis, we utilized structural equation modeling (SEM) parameter estimates to determine the relationship between aging and memory, as mediated by growth hormone (GH) levels (indirectly measured through the insulin-like growth factor system), P300 latency and TOVA, putative neurocognitive predictors tested in this study. An SEM was developed hypothesizing a causal directive path, leading from age to memory, mediated by IGF-1 and IGF-BP3, P300 latency (speed), and TOVA decrements. An increase in age was accompanied by a decrease in IGF-1 and IGF-BP3, an increase in P300 latency, a prolongation in TOVA response time, and a decrease in memory functioning. Moreover, independent of age, decreases in IGF-1 and IGF-BP3, were accompanied by increases in P300 latency, and were accompanied by increases in TOVA response time. Finally, increases in P300 latency were accompanied by decreased memory function, both directly and indirectly through mediation of TOVA response time. In summary, this is the first report utilizing SEM to reveal the finding that aging affects memory function negatively through mediation of decreased IGF-1 and IGF-BP3, and increased P300 latency (delayed attention and processing speed).
Collapse
Affiliation(s)
| | - Thomas J. H. Chen
- Chang Jung Christian University, Taiwan, People’s Republic of China
- Changhua Christian Hospital, Changhua, Taiwan People’s Republic of China
| | - Thomas J. Prihoda
- Department of Pathology, University Of Texas Health Science Center, San Antonio, Texas USA
| | - William Sonntag
- Department of Physiology & Pharmacology, Wake Forest University School Of Medicine, Winston-Salem, North Carolina USA
| | - Brian Meshkin
- Department of Molecular Nutrition & Nutrigenomics, Salugen, Inc., San Diego, California USA
| | - B. William Downs
- Natural Products Division & Research, Allied Nutraceutical Research, Lederach, Pennsylvania USA
| | - Julie F. Mengucci
- Department of Psychoneurogenetics, Synaptamine, Inc., San Antonio, Texas USA
| | - Seth H. Blum
- Department of Psychoneurogenetics, Synaptamine, Inc., San Antonio, Texas USA
| | - Alison Notaro
- PATH Research Foundation, New York, NY USA
- Cleveland Clinic, Toronto, Ontario Canada
| | | | | | - Kenneth Blum
- PATH Research Foundation, New York, NY USA
- Department of Physiology & Pharmacology, Wake Forest University School Of Medicine, Winston-Salem, North Carolina USA
- Department of Molecular Nutrition & Nutrigenomics, Salugen, Inc., San Diego, California USA
- Department of Psychoneurogenetics, Synaptamine, Inc., San Antonio, Texas USA
| |
Collapse
|